Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06665542 · ClinicalTrials.gov registry record
A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.
A clinical trial of Sepsis and Acute Infection, sponsored by MeMed Diagnostics.
- Active
- Registry status
- 2,000
- Enrollment target
- 8
- Study locations
NCT06665542: Active study of Sepsis and Acute Infection, sponsored by MeMed Diagnostics.
NCT06665542 is a study of Sepsis and Acute Infection that is active but no longer recruiting, run by MeMed Diagnostics. The registered enrollment target is 2,000 participants, below the 6,542-participant average among 90 other Sepsis trials with a reported enrollment target (69% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06665542, a study of Sepsis and Acute Infection, is active but no longer recruiting, sponsored by MeMed Diagnostics.
- ACTIVE NOT RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 8
- Study locations
Study Summary
The study is a multi-center, prospective, observational clinical study enrolling patients from at least 3 medical centers. Study population will include patients over the age of 18 years. The study will recruit patients presenting with suspicion of acute infection/sepsis and healthy individuals. Study main objective is to derive and verify a host response based score to predicte severe outcome.
Primary Outcome
To derive and verify the diagnostic performance of a host-response tool based on novel biomarkers for predicting disease severity in adult patients, aged 18 years or older, presenting with clinical suspicion of acute infection/sepsis.
Conditions Studied
Study Locations (8)
Other
- Carmel MC - Haifa
- Rambam MC - Haifa
- Edith Wolfson MC - Holon
- Shaare Zedek MC - Jerusalem
- Beilinson MC - Petah Tikva
- Sheba Tel-HaShomer MC - Tel Aviv
New York
- Maimonides MC - New York
Wisconsin
- MCW - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT06665542 still lists
NCT06665542 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, below the 6,542-participant average among 90 other Sepsis trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 0 interventions.
NCT06665542 lists 8 locations in 3 states (Other, New York, Wisconsin).
Frequently Asked Questions
What is clinical trial NCT06665542 about?
NCT06665542 is a clinical study titled "A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.". The study is a multi-center, prospective, observational clinical study enrolling patients from at least 3 medical centers. Study population will include patients over the age of 18 years. The study will recruit patients presenting with suspicion of acute infection/sepsis and healthy individuals. S...
What is the current status of trial NCT06665542?
This trial is currently active not recruiting. The enrollment target is 2,000 participants. The study started on 2020-11-12. Estimated completion is 2025-12-31.
What conditions does trial NCT06665542 study?
This clinical trial studies the following conditions: Sepsis, Acute Infection.
Who is sponsoring clinical trial NCT06665542?
This trial is sponsored by MeMed Diagnostics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06665542 being conducted?
This trial has 8 study locations across New York, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06665542's enrollment target sits among peer trials
2,000 16th of 90 higher than 75 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI